CLINICAL TRIALS

We have a variety of ongoing clinical trials in different therapeutic areas, which are detailed below. If you have any questions about any of these trials, contact our Medical Affairs team via email medicalaffairs@immunogen.com or by phone (+1-781-895-0115).

ACUTE MYELOID LEUKEMIA (AML)
ClinicalTrials.gov Identifier: NCT04086264
IMGN632 (Pivekimab Sunirine) as a Monotherapy or with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (Study 802)
Status: Recruiting

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
ClinicalTrials.gov Identifier: NCT03386513
Study of IMGN632 (Pivekimab Sunirine) in Patients with Untreated BPDCN and Relapsed/Refractory BPDCN (CADENZA)
Status: Recruiting
More Information: https://immunogenclinicaltrials.com/bpdcn/

OVARIAN CANCER
ClinicalTrials.gov Identifier: NCT04209855
A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (MIRASOL)
Status: Active, Not Recruiting

ClinicalTrials.gov Identifier: NCT05041257
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)
Status: Recruiting

ClinicalTrials.gov Identifier: NCT05445778
Mirvetuximab Soravtansine with Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Status: Recruiting

ClinicalTrials.gov Identifier: NCT05456685
Mirvetuximab Soravtansine (IMGN853) with Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer (Study 420)
Status: Recruiting

More Information: https://immunogenclinicaltrials.com/study420/

ClinicalTrials.gov Identifier: NCT05527184
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Status: Recruiting

OTHER SOLID TUMORS
ClinicalTrials.gov Identifier: NCT04622774
First-in-Human Study of IMGC936 in Patients with Advanced Solid Tumors
Status: Recruiting

ImmunoGen’s investigational products have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. The safety and efficacy of investigational products have not been established.